Identification of Therapeutic Gene Targets in Triple-Negative Breast Cancer: A Hybrid Approach Integrating Semidefinite Programming, Boolean Simulation, and Druggability Analysis
Preprint
Abstract
Triple-negative breast cancer (TNBC) represents a significant clinical challenge due to the absence of well-established molecular targets and resistance to conventional therapies. Identifying synergistic combinations of therapeutic targets requires computational approaches that integrate topological network analysis, experimental validation, and clinical applicability. This work proposes a hybrid methodology that combines Semidefinite Programming (SDP) for identification of critical nodes in gene regulatory networks, Boolean simulation for quantification of perturbation efficacy, and systematic literature validation with focus on druggability and synergy. We constructed a core regulatory network of 13 genes representing key nodes in STAT3, PI3K/AKT, and p53 signaling pathways, which are frequently deregulated in TNBC. We applied three complementary SDP formulations (Max-Cut, Influence Maximization, and Spectral Clustering) to identify candidate targets, followed by stochastic Boolean simulation for calculation of the Therapeutic Index (TI). We integrated a practical applicability scoring system that considers druggability, clinical evidence, specificity, and TNBC validation. Our analysis identified the combination STAT3 + BCL2 as the most promising therapeutic pair, with an applicability score of 0.905 and average druggability of 0.85. This finding is strongly supported by extensive experimental evidence demonstrating that STAT3 directly regulates BCL2 transcription in breast cancer cells. We demonstrate a clear methodological evolution from previous approaches: from 5 genes (Tilli et al., 2016, druggability 0.32) to 3 genes ([9], druggability 0.40) and finally to 2 genes (our work, druggability 0.85), representing a 166% increase in druggability and 60% reduction in complexity. The proposed methodology offers a systematic and reproducible framework for prioritization of therapeutic targets with focus on clinical applicability, contributing to rational development of combination therapies in TNBC.Keywords
This publication has 33 references indexed in Scilit:
- Optimizing therapeutic targets for breast cancer using boolean network modelsComputational Biology and Chemistry, 2024
- Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trialThe Lancet Gastroenterology & Hepatology, 2018
- Triple-negative breast cancer: challenges and opportunities of a heterogeneous diseaseNature Reviews Clinical Oncology, 2016
- Targeting BCL-2 with the BH3 Mimetic ABT-199 in Estrogen Receptor-Positive Breast CancerCancer Cell, 2013
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing plateletsNature Medicine, 2013
- The BCL-2 protein family: opposing activities that mediate cell deathNature Reviews Molecular Cell Biology, 2008
- How many drug targets are there?Nature Reviews Drug Discovery, 2006
- Convex Optimization2004
- Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cellsOncogene, 2002
- The druggable genomeNature Reviews Drug Discovery, 2002